Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been determined in breast cancers. Interferons can affect T-cell activity through direct and indirect mechanisms. Myxovirus resistance A (MxA) is an excellent marker of interferon activity. Here, we evaluated TILs and MxA expression in human epidermal growth factor receptor 2 (HER2)–positive breast cancers. Materials and Methods Ninety cases of hormone receptor (HR)+/HER2+ tumors and 78 cases of HR–/HER2+ tumors were included. The TILs level was assessed using hematoxylin and eosin–stained full face sections, and MxA expression was evaluated by immunohistochemistry with a tissue microarray. Results MxA protein expression was significantly higher in tumors with high histologic grade (p=0.023) and high levels of TILs (p=0.002). High levels of TILs were correlated with high histological grade (p=0.001), negative lymphovascular invasion (p=0.007), negative lymph node metastasis (p=0.007), absence of HR expression (p < 0.001), abundant tertiary lymphoid structures (TLSs) around ductal carcinoma in situ (p=0.018), and abundant TLSs around the invasive component (p < 0.001). High levels of TILs were also associated with improved disease-free survival, particularly in HR–/HER2+ breast cancers. However, MxA was not a prognostic factor. Conclusion High expression of MxA in tumor cells was associated with high levels of TILs in HER2-positive breast cancers. Additionally, a high level of TILs was a prognostic factor for breast cancer, whereas the level of MxA expression had no prognostic value.
Abstract
Purpose The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been determined in breast cancers. Interferons can affect T-cell activity through direct and indirect mechanisms. Myxovirus resistance A (MxA) is an excellent marker of interferon activity. Here, we evaluated TILs and MxA expression in human epidermal growth factor receptor 2 (HER2)–positive breast cancers. Materials and Methods Ninety cases of hormone receptor (HR)+/HER2+ tumors and 78 cases of HR–/HER2+ tumors were included. The TILs level was assessed using hematoxylin and eosin–stained full face sections, and MxA expression was evaluated by immunohistochemistry with a tissue microarray. Results MxA protein expression was significantly higher in tumors with high histologic grade (p=0.023) and high levels of TILs (p=0.002). High levels of TILs were correlated with high histological grade (p=0.001), negative lymphovascular invasion (p=0.007), negative lymph node metastasis (p=0.007), absence of HR expression (p < 0.001), abundant tertiary lymphoid structures (TLSs) around ductal carcinoma in situ (p=0.018), and abundant TLSs around the invasive component (p < 0.001). High levels of TILs were also associated with improved disease-free survival, particularly in HR–/HER2+ breast cancers. However, MxA was not a prognostic factor. Conclusion High expression of MxA in tumor cells was associated with high levels of TILs in HER2-positive breast cancers. Additionally, a high level of TILs was a prognostic factor for breast cancer, whereas the level of MxA expression had no prognostic value.
참고문헌 (29)
- 안성귀, "Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer", Journal of Pathology and Translational Medicine, 49(5), pp.355~363 (2015), 대한병리학회[DOI]
- Stagg J, "Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy", Proc Natl Acad Sci U S A, 108, pp.7142~7147 (2011)
- Lee HJ, "Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab", Am J Clin Pathol, 144, pp.278~288 (2015)
- Salgado R, "The evaluation of tumor-infiltrating lymphocytes(TILs)in breast cancer : recommendations by an International TILs Working Group 2014", Ann Oncol, 26, pp.259~271 (2015)
- Schlee M, "Master sensors of pathogenic RNA : RIG-I like receptors", Immunobiology, 218, pp.1322~1335 (2013)
- Weichselbaum RR, "An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer", Proc Natl Acad Sci U S A, 105, pp.18490~18495 (2008)
- Laplante M, "mTOR signaling in growth control and disease", Cell, 149, pp.274~293 (2012)
- Hu JL, "Structural analysis of tumor-related single amino acid mutations in human MxA protein", Chin J Cancer, 34, pp.583~593 (2015)
- Haller O, "Mx GTPases : dynamin-like antiviral machines of innate immunity", Trends Microbiol, 23, pp.154~163 (2015)
- Takeuchi O, "Pattern recognition receptors and inflammation", Cell, 140, pp.805~820 (2010)
- Lee HJ, "High mobility group B1 and N1(HMGB1 and HMGN1)are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers", Virchows Arch, 467, pp.701~709 (2015)
- Borden EC, "Interferons at age 50 : past, current and future impact on biomedicine", Nat Rev Drug Discov, 6, pp.975~990 (2007)
- Crouse J, "Regulation of antiviral T cell responses by type I interferons", Nat Rev Immunol, 15, pp.231~242 (2015)
- Simmons DP, "Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing", J Immunol, 188, pp.3116~3126 (2012)
- Minn AJ, "Interferons and the immunogenic effects of cancer therapy", Trends Immunol, 36, pp.725~737 (2015)
- Calmon MF, "Epigenetic silencing of CRABP2 and MX1 in head and neck tumors", Neoplasia, 11, pp.1329~1339 (2009)
- Mushinski JF, "Inhibition of tumor cell motility by the interferoninducible GTPase MxA", J Biol Chem, 284, pp.15206~15214 (2009)
- Brown SG, "Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and docetaxel induced apoptosis", Prostate, 75, pp.266~279 (2015)
- Croner RS, "Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis", Int J Cancer, 135, pp.2878~2886 (2014)
- Huber M, "Comparison of proteomic and genomic analyses of the human breast cancer cell line T47D and the antiestrogen-resistant derivative T47D-r", Mol Cell Proteomics, 3, pp.43~55 (2004)
- Becker M, "Distinct gene expression patterns in a tamoxifensensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366", TAM, 2005, pp.4, 151~168
- Johansson HJ, "Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer", Clin Proteomics, 12, pp.8~ (2015)
- Sistigu A, "Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy", Nat Med, 20, pp.1301~1309 (2014)
- Farmer P, "A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer", Nat Med, 15, pp.68~74 (2009)
- Goc J, "Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+T cells", Cancer Res, 74, pp.705~715 (2014)
- Martinet L, "Human solid tumors contain high endothelial venules : association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer", Cancer Res, 71, pp.5678~5687 (2011)
- Cancer Genome Atlas Network, "Comprehensive molecular portraits of human breast tumours", Nature, 490, pp.61~70 (2012)
- Harvey JM, "Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer", J Clin Oncol, 17, pp.1474~1481 (1999)
- Lee HJ, "Two histopathologically different diseases : hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer", Breast Cancer Res Treat, 145, pp.615~623 (2014)